Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cerus Appoints COO Vivek Jayaraman To Company President And CEO Position Effective July 1

2026-03-16

Cerus's Record 2025 Sets It Up For Another Leg Higher

2026-03-05
CERS’ INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They’ve also grown their adoption across ~40 countries.

Cerus shares are trading lower after the company reported worse-than-expected Q4 sales results.

2026-03-03

MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

2026-03-03
MDB stock fell 27.2% in pre-market trading after reporting Q4 earnings of $1.65 per share, revenue of $695.07M, and Q1 guidance below estimates.

Cerus Corp (NASDAQ:CERS) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss

2026-03-02
Cerus Corporation reports Q4 2025 revenue miss and wider loss, but highlights record annual product sales and strong growth for its blood safety platforms.

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

2026-03-02

12 Health Care Stocks Moving In Monday's After-Market Session

2026-03-02

Cerus Q4 Earnings Assessment

2026-03-02

Cerus Affirms FY2026 Sales Guidance of $224.000M-$228.000M

2026-03-02
Cerus (NASDAQ:CERS) affirms FY2026 sales outlook from $224.000 million-$228.000 million to $224.000 million-$228.000 million.

Cerus Q4 EPS $(0.01), Inline, Sales $57.751M Miss $58.075M Estimate

2026-03-02
Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $57.751 million